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Evaluation of a computer-assisted method for individualized 
anticoagulation: Retrospective and prospective studies with a 
pharmacodynamic model 
We studied the effectiveness of a computer program based on a mathematic model of warfarin 
dynamics in assisting with the initial phases of anticoagulation. In retrospective evaluations the 
program was successful in predicting prothrombin complex activity (PCA) responses for three 
different groups of subjects, indicating that the model is a good representation of the physiologic 
system. In a prospective evaluation of the program a computer-assisted group of 10 patients 
was compared with a control group of 10 patients who did not receive computer assistance. 
Because of the program's very conservative upper limits for warfarin dosage in the first few 
days of therapy, the computer-assisted patients required slightly more time (6 days), on the 
average, to first reach PCA values in the 20% to 30% therapeutic range than did the control 
patients (4.8 days). After the desired PCA had been achieved, however, the computer-assisted 
group remained within the therapeutic range for 83% of the time compared to only 60% for the 
control group. This difference was due primarily to much less overanticoagulation of the 
computer-assisted patients than of the controls. 
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Our objective was to evaluate a new com- 
puter-assisted method for individualizing anti- 
coagulant therapy. Initial anticoagulation with 
oral drugs is a difficult task for the physician. 
Patients vary widely in their responses to oral 
anticoagulants. Although attempts have been 
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made to predict individual anticoagulant dosage 
on the basis of characteristics such as body 
weight,5 no simple laboratory test or physical 
measurement has been found that can be used to 
estimate reliably a patient's maintenance dose 
before beginning therapy. In addition, the max- 
imal effect of a single dose of warfarin on the 
prothrombin complex activity (PCA) develops 
36 to 54 hr after the dose is given, so that the 
effects of daily dosing are cumulative and dif- 
ficult to predict on an intuitive basis. 
Methods for initiating oral anticoagulation 
should minimize the time required to achieve 
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steady-state PCA values within the therapeutic 
range while protecting the patient from the pos- 
sibility of overdosage and hemorrhage. It is 
difficult to evaluate the degree to which con- 
ventional methods achieve this goal, since no 
detailed studies have been reported on varia- 
tions in the PCA during the initiation of oral 
anticoagulation. There are, however, several 
studies that document the fact that PCA control 
tends to be suboptimal even during the mainte- 
nance phase. Brotman2 found that under most 
circumstances one could expect to have a pa- 
tient within the therapeutic range no more than 
55% to 65% of the time and Mosely et al.6 
reported that at any given time only 65% of 
their patients were within therapeutic limits. 
Shapiro et al." found that patients treated with 
oral drug were within the therapeutic range 71% 
of the time, but the therapeutic limits for PCA 
they used (11% to 26%) were much wider than 
is usually accepted at present. Pollard et al." 
reported results similar to those of Shapiro et al. 
The large variations in PCA that occur during 
long-term anticoagulation underscore the dif- 
ficulties of dosage determination during the 
initiation of anticoagulation when there is no 
previous experience from which to predict a pa- 
tient's response. As a result, the initial phase of 
anticoagulation is often unsatisfactory. 
Despite the difficulties it is very important to 
identify an appropriate maintenance dose as 
soon as possible after beginning therapy. In- 
adequate anticoagulation may increase the risk 
of thrombosis, while overanticoagulation car- 
ries the risk of severe hemorrhage. Because of 
the importance and difficulty of achieving ade- 
quate anticoagulation rapidly and safely, an at- 
tempt to use a more rigorous method for esti- 
mating anticoagulant dosage during initiation 
phases is justified. 
Several groups have recently reported meth- 
ods that correlate either the time required to 
reach a specified level of anticoagulation during 
the loading phase"' 13 or the area under the 
prothrombin time-dose curve" with the ulti- 
mately required maintenance dose. While these 
methods are an important advance, they have 
not proved to be suitable for all patients.4' 5 
In another approach, computer models have 
been used to predict PCA response to warfarin 
during retrospective study of the initial phase of 
anticoagulation"' 17 and prospectively during 
long-term anticoagulation,3' 18 but they have not 
been used as an adjunct during the initiation of 
oral anticoagulant therapy. Mathematic models 
suitable for assisting in initial anticoagulation 
have been described,7 but none has been used in 
a computer program to assist the physician. 
None of the reported models provides a mech- 
anistic framework potentially useful for the 
study of other aspects of warfarin pharmacol- 
ogy, such as interactions of warfarin with other 
drugs. 
We have approached the problem by propos- 
ing a model8' 9" 11 warfarin effect on plasma 
prothrombin activity that is based in part on the 
enzyme-substrate formulation of Sellers and 
Koch-Wesser." Our model assumes rapid ab- 
sorption of warfarin so that the total body war- 
farin at a time t is given by 
Q(t) = C, exp[(t - t,)] 
= 
where Q(t) is the total body warfarin (mg), Ice is 
the warfarin elimination rate constant (days-1), 
and Ci is the dose of warfarin (in mg) given at 
time ti. 
Free warfarin depresses the prothrombin 
complex activity in a time-dependent manner 
according to the differential equation 
dP 
dt = Sm (1 aQ(t) + kPP (2) 
aQ(t) 
where a is the free fraction of warfarin divided 
by the distribution volume (1-'), Sm is the max- 
imum rate of prothrombin complex synthesis 
(% of control/day), is the prothrombin com- 
plex degradation rate constant (days-1), P is the 
prothrombin complex activity in plasma (% of 
control), and km is the free plasma warfarin 
concentration at half maximal P (mg//). 
The prothrombin time, measured by the Quick 
technique, is converted to percent activity by the 
relationship PCA = [(Protime-B)/A]' (where, 
for example, A = 230 and B = 8.2 for group 
R- 1, defined below). 
Here we summarize the success of a computer 
program based on the above model in predicting 
prothrombin complex response to warfarin in 
retrospective studies of normal volunteers and 
( 1) 
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hospitalized patients. We also present the results 
of a trial of the model's effectiveness in guiding 
therapy in a prospective study in patients receiv- 
ing anticoagulant therapy after cardiac surgery 
and pulmonary embolism. 
Brief description of the program 
In general, the parameters a, Ice, km, k, and 
Sm in the system equations must be determined 
for each patient. However, since the free frac- 
tion of warfarin would be expected to be rela- 
tively constant in patients not receiving drugs 
that affect warfarin binding," the same value 
for c,: (0.0l)' was used for all of the subjects in 
the studies presented here. This reduced the 
number of parameters that needed to be iden- 
tified from the experimental data and thus en- 
abled earlier identification of the other parame- 
ters. However, the program could be altered to 
allow for situations in which the fraction of un- 
bound warfarin differs from normal, e.g., when 
the patient is also receiving drugs such as 
phenylbutazone that decrease warfarin binding. 
In cases in which there is no competitive drug 
binding, a different a would change the value of 
km computed for any individual patient pro- 
portionately and would not affect his or her rec- 
ommended doses or predicted PCAs. The pa- 
rameters ke and km are determined for each pa- 
tient by a nonlinear least-squares procedure that 
minimizes the sums of the squares of the differ- 
ences between measured PCA values and those 
predicted by the model for the corresponding 
times. There are a variety of identification 
techniques that could be used to obtain the best 
combination of values for the parameters ke and 
km. To minimize computation time, however, a 
set of possible parameter values that includes 10 
different ke values and 10 different km values is 
examined to determine which combination of 
the two parameters gives the lowest sum of 
squares of the differences between measured 
and predicted values.9 
In operation the program requires as initial 
information the value of the PCA at the time 
that anticoagulation is begun. Subsequently, the 
daily doses of warfarin and PCA values are en- 
tered as obtained. Since early in the course of 
anticoagulation there are insufficient data for 
more meaningful recommendations, doses of 5 
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Table I. Program limitations on maximum 
warfarin dosage recommendations 
mg are given on each of the first 2 days of 
therapy, regardless of PCA values. Thereafter, 
after identification of the patient parameters, the 
program uses the system equations to predict 
the daily maintenance dose that will maintain 
the PCA as close to 25% (the middle of our 
therapeutic range) as possible. This is offered as 
the next suggested dose, as long as it does not 
fall outside of certain limits intended to keep the 
recommended dose from rising too rapidly early 
in therapy and it does not exceed 20 mg/day. 
The maximum dose recommended by the pro- 
gram is set as follows: day 3, 7.5 mg; day 4, 10 
mg; day 5, 15 mg; and thereafter, 20 mg. Addi- 
tional constraints are placed on the maximum 
allowable increase in dose according to the 
schedule in Table I. By placing these con- 
straints on the program, we sought to prevent 
excessively large doses being recommended 
during the early phases of anticoagulation, 
when the patient parameters have not yet been 
identified reliably, even though this limitation 
may slightly increase the time required initially 
to decrease the PCA measurement to the thera- 
peutic range. 
The program provides a set of instructions 
that may be displayed on a terminal or printer. 
After reading the instructions, which requires 
only 2 or 3 min, the physician may use the 
program in an interactive fashion in which the 
computer prompts the user for all required in- 
put. When he first wishes assistance in an- 
ticoagulating a patient, the physician creates a 
file to hold all the patient's anticoagulation data. 
Any time after this he uses the dosing program, 
which asks for the most recent warfarin dosages 
and PCA values. The program then computes 
the dynamic parameters, the expected responses 
to several possible doses of warfarin, and the 
recommended dose. These values are then dis- 
5.0 7.5 
7.5 10.0 
10.0 15.0 
15.0 20.0 
Highest dose given New maximum dose 
previously (mg/day) (mg/day) 
MR 
Warfarin? 
5. 
Prothrombin? 
81. 
Most Probable True Protime 30. 
Performance to Date Expected Response 
Dose PCA Dose PCA 
5.00 81.00 0.0 27.8 
5.00 73.00 0.5 27.6 
A 5.00 49.00 1.0 27.5 
5.00 48.00 2.0 27.2 
7.50 38.00 2.5 27.1 
7.50 30.00 3.0 27.0 
7.50 31.00 4.0 26.8 
5.0 26.6 
7.5 26.2 
10.0 25.8 
MR 
Prothrombin Complex Activity 
Day Dose 0 50 100 
0 0.0 
1 5.0 
2 5.0 
3 5.0 
4 5.0 
5 7.5 
6 7.5 
7 7.5 
8 6.0 
Recommended Warfarin 6.00 MG 
Predicted PCA 26.4% 
Fig. 1. Example of computer terminal output for a 
patient who received six daily warfarin doses. "Most 
probable PCA" is derived from an average of the 
most recent measurement and the most recent value 
computed by the program. Table A summarizes the 
dosage history and PCA response to date. Table B 
shows values for the next day's PCA predicted by the 
program for different warfarin doses. 
played at the terminal along with graphic and 
tabular summaries of the patient's anticoagula- 
tion therapy to date. Although the program 
works best if daily PCA measurements are 
available, it can be used even for patients for 
whom some data are missing. The output from a 
typical terminal session is shown in Fig. 1. 
Retrospective evaluation of program 
performance 
Retrospective evaluations of the program 
were done to assess its reliability and safety 
before it was used for prospective guidance of 
patient therapy. To obtain as broad as possible 
an evaluation, we used data from our own lab- 
oratories and that reported by another labora- 
tory.' In the retrospective studies the program 
was used to predict each patient's dynamic pa- 
rameters for each day by use of all of the previ- 
ously measured PCA values for that patient. 
From these parameters and the prescribed dose 
the program then predicted the patient's PCA 
value for the next day (henceforth referred to as 
the "predicted" PCA response). Beginning at 
the initiation of therapy, the calculation was re- 
peated for each subsequent day of treatment. 
Three different groups of subjects were used 
in the retrospective studies. Group R-1 con- 
sisted of 10 normal men at the University of 
Michigan Medical Center (UMMC) who had 
received 7.5 mg/day sodium warfarin for 14 
days. Group R-2, data for which were taken 
from a study reported by Aggeler and O'Reilly,' 
consisted of 15 normal subjects given 10 
mg/day warfarin for 6 days. Group R-3 con- 
sisted of 17 UMMC patients selected randomly 
from the records of patients anticoagulated after 
cardiac surgery or pulmonary embolism. 
The program's predictions of warfarin 's ef- 
fects on PCA were in all cases reasonable; the 
accuracy of these predictions tended to increase 
as more data became available for each patient. 
In most cases the predicted PCA values were 
quite close to the measured values by the third 
to fourth day after the beginning of treatment; 
this was in accordance with the results of our 
previous investigations.9 The maintenance dose 
recommended by the program usually became 
stable (defined as remaining within a 1.0-mg 
range for 3 successive days) by the fourth to 
sixth day after starting warfarin administration 
(Table II). The program's dosage recommen- 
dations appeared reasonable in all cases. 
To obtain a quantitative estimate of program 
performance, we calculated the normalized de- 
viation of the predicted PCA value from the 
measured PCA value 
E = Observed PCA - 
Predicted PCA /Observed PCA 
for each data point. Fig. 2 compares the average 
daily PCA deviations of groups R-2 and R-3. 
The average deviations decreased with time for 
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Table II. Cumulative percentage of patients 
whose computer-recommended doses had 
stabilized by given day of therapy 
both groups due to increasingly better estimates 
of the dynamic parameters as more data points 
became available. The smaller average devia- 
tions found for group R-2 compared to group 
R-3 were probably due to the constant dosing 
schedule used by Aggeler and O'Reilly.' It is 
also likely that the patients in group R-3 were 
exposed to more factors that affect warfarin re- 
sponse, such as the presence of interacting 
drugs, than were the normal subjects of group 
R-2. 
The generally good agreement between the 
predicted and observed PCA values in all three 
retrospective trials established the model as a 
good representation of the physiologic system 
with adequate reliability to justify a prospective 
trial in patients. 
Prospective evaluation of program 
performance 
Program assistance was provided for a total 
of 10 patients undergoing initial anticoagula- 
tion. All but one patient considered in this phase 
of the study were receiving anticoagulant ther- 
apy postoperatively on the cardiac surgery ser- 
vice at UMMC. These patients are routinely 
placed on prolonged therapy after coronary ar- 
tery bypass surgery or implantation of pros- 
thetic heart valves. The remaining patient was 
anticoagulated after acute pulmonary embo- 
lism. The house staff responsible for the pa- 
tients' clinical care decided when oral an- 
ticoagulant should be initiated. 
Patients were considered eligible for our 
study if: (1) they had PCA of 70% or more at 
the onset of oral anticoagulation, (2) they were 
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TIME AFTER INITIATION OF THERAPY, DAYS 
Fig. 2. Normalized average deviations of predicted 
PCA values from observed values in two of the retro- 
spective studies. Points shown as (o) were computed 
from the data of Aggeler and O'Reilly' (group R-2). 
Points shown as (e) were computed for UMMC pa- 
tients (group R-3). 
afebrile, and (3) they had received either no 
warfarin or not more than two 5-mg doses at the 
time we were informed of their availability for 
study. 
A control group (group P-C) of 10 patients 
was anticoagulated without computer assis- 
tance. These patients were matched with the 
computer-assisted patients on the basis of age 
and diagnostic category and were treated on the 
same services as the computer-assisted group. 
Thus, the control group also consisted of nine 
patients who had undergone heart surgery and 
one patient anticoagulated for thrombophlebitis. 
Mean age for each group was 52 yr. 
Each day, shortly after PCA values were re- 
ceived from the anticoagulation laboratory, we 
placed sheets in the order books informing the 
house staff of the PCA for that day and the 
program's current dosage recommendations. 
The house staff either prescribed the recom- 
mended dosage or modified it on the basis of 
clinical judgement. 
Fig. 3 shows the recommended warfarin 
doses for one of these patients along with the 
computer-predicted and observed PCA values. 
The responses of the remaining patients were on 
the same order. Fig. 4 gives the average per- 
centage deviations of the predicted PCA values 
from the observed values for the computer- 
uJ 
= 20 a- 
1 
cc 10 IJJ 
2 3 4 5 6 7 8 9 10 
Day 
Retrospective 
(group R-3) 
Computer- 
assisted 
(group P-1) 
Control 
(group P-C) 
1 17 
2 17 22 
3 33 10 67 
4 59 40 78 
5 67 70 89 
6 83 80 89 
7 91 90 89 
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100 KU 
MEASURED VALUE 
PREDICTED VALUE 
5 5 5 3 3 3 4 4 DOSE, mg 
2 3 4 5 6 7 8 9 10 
TIME AFTER INITIATION OF THERAPY, DAYS 
Fig. 3. Measured and predicted PCA responses for patient K. U. (group P-1) in prospective study 
with program assistance. 
assisted group. The agreement between the 
measured and the predicted PCA values is good 
and improves as the number of days of therapy 
increases. 
The number of days required to bring the 
PCA into the therapeutic (20% to 30%) range 
and the percentage of subsequent days within 
the therapeutic range were computed for each 
member of the computer-assisted and control 
groups (Table III). When distributional require- 
ments appeared to be satisfied, the results were 
tested for significance by Student's t test. 
Otherwise, the Wilcoxon rank-sum test was 
used. The average number of days required to 
first reach the therapeutic range was greater for 
the computer-assisted than for the control pa- 
tients (P < 0.05 by Student's t test). This addi- 
tional time, however, did not prolong patients' 
hospital stays; continued hospitalization was re- 
quired for other reasons. More importantly, 
after once having reached the therapeutic range, 
the program-assisted group remained within the 
therapeutic range for a much larger percentage 
of the time (P < 0.01). This indicates that the 
maintenance dose was estimated with much 
greater accuracy in the computer-assisted 
group. 
It is apparent from Table III that the differ- 
ence in percentage of time spent within the ther- 
apeutic range for the two groups reflects 
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primarily the fact that the program-assisted pa- 
tients were not overanticoagulated during ther- 
apy. This suggests that computer-assisted pa- 
tients should be at a lower risk of hemorrhage 
than those who did not receive computer- 
assisted therapy. 
Discussion 
We have presented results of what we believe 
to be the first clinical use of a mathematic model 
of warfarin dynamics to guide initiation of oral 
anticoagulant therapy. We did both retrospec- 
tive and prospective evaluations of a computer 
program based on the model, which used data 
obtained both in our laboratory and from the 
literature. The program does a creditable job of 
predicting patient response to anticoagulants in 
the retrospective studies, thus indicating that the 
model is a reasonable empirical representation 
of the physiologic system's performance during 
the initial phases of anticoagulation. These re- 
sults are confirmed by prospective study. We 
demonstrated that the use of such a program 
results in the PCA values remaining within the 
therapeutic range for an increased percentage of 
the time. 
Rapid identification of a patient's kinetic and 
dynamic parameters is probably only one reason 
for the program's increased success in maintain- 
ing patients within the therapeutic range. It also 
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1 2 3 4 5 6 7 0 9 10 
TIME AFTER INITIATION OF THERAPY, DAYS 
Fig. 4. Average percent deviations of predicted PCA values from observed values for all patients 
anticoagulated with program assistance (group P-1). 
Table III. Prospective comparison of computer-assisted and control groups 
Percent days within 
therapeutic range* 
Percent days below 
therapeutic range* 
Percent days above 
therapeutic range* 
Days required to achieve 
therapeutic range 
Data in parenthesis are ranges. 
*After first achieving therapeutic range. 
tBy Wilcoxon rank-sum test. 
#By Student's t test. 
appears likely that the program's maximum 
dose limitations reduce the probability of giving 
a dose early in therapy that will drive the PCA 
below 20%. Once the patient parameters have 
been identified adequately, the program also 
tends to limit the frequency and magnitude of 
changes in dosage in response to small changes 
in PCA. This may counteract a tendency of in- 
experienced physicians to react to every change 
in PCA with a concomitant change in warfarin 
dose, with resultant overcontrol and undesirable 
cycling of PCA above and below the desired 
limits. 
Correlation methods, such as those relating 
ultimate maintenance requirements to the PCA 
values at a fixed time during a standard loading 
therapy, seem less satisfactory than the method 
we have presented. Dosages obtained by the 
correlation methods may vary widely from the 
"true" maintenance doses in some patients. 
Such methods often use only a small portion of 
the available data from each patient. In contrast, 
the computer-assisted approach we present here 
uses all the prothrombin and dosage information 
obtained on each patient. The method updates 
its predictions and recommendations as each 
new datum is obtained and is applicable at any 
stage of therapy Finally, it is capable of ac- 
counting for changes in the patient's physio- 
logic status with time, as reflected in kinetic and 
dynamic parameters. 
Although further studies are required to de- 
60 (33-100) 83 (40-100) <0.01t 
29 (0-50) 6 (0-60) <0.05t 
11(0-67) 11(0-50) N.S.t 
4.33 (1-8) 6.00 (4-9) <0.05t 
Control Computer-assisted 
(group P-C) (group P-1) 
termine the method's range of applicability, re- 
sults thus far support our belief that the com- 
puter-assisted approach described here may lead 
to improved control of oral anticoagulation. 
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